Jazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow JAZZ
Jazz Pharmaceuticals PLC (JAZZ) Altman Z-score
Jazz Pharmaceuticals PLC's Altman Z-score for fiscal 2025 is 1.37, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 1.37 | (0.24) |
| FY2024 | 1.60 | 0.18 |
| FY2023 | 1.42 | 0.05 |
| FY2022 | 1.37 | 0.25 |
| FY2021 | 1.12 | (2.01) |
| FY2020 | 3.12 | (0.22) |
| FY2019 | 3.35 | 0.34 |
| FY2018 | 3.01 | (0.07) |
| FY2017 | 3.08 | 0.73 |
| FY2016 | 2.35 | (2.03) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.16 | — | 0.20 | |
| Retained earnings / total assets | 0.06 | — | 0.08 | |
| EBIT / total assets | (0.04) | — | −0.12 | |
| Market value of equity / total liabilities | 1.41 | — | 0.85 | |
| Sales / total assets | 0.37 | — | 0.37 | |
| Altman Z-score | Distress zone | 1.37 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Grey zone | 1.63 | ||
Z and Z″ put Jazz Pharmaceuticals PLC in different zones: distress zone by Z, grey zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| TECH Bio-Techne Corp compare | 15.5× |
| CORT Corcept Therapeutics Incorporated compare | 14.1× |
| EXEL Exelixis, Inc. compare | 12.7× |
| BMRN BioMarin Pharmaceutical Inc. compare | 5.7× |
| HALO Halozyme Therapeutics, Inc. compare | 3.5× |
| ASND Ascendis Pharma A/S compare | 2.0× |
| JAZZ Jazz Pharmaceuticals PLC | 1.4× |
| SMMT Summit Therapeutics PLC compare | 0.9× |
| BBIO BridgeBio Pharma, Inc. compare | −3.5× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets